多西他赛联合顺铂腹腔热灌注治疗恶性腹水的疗效

To observe the clinical effects of docetaxel combined with cisplatin hyperthermic intraperitoneal chemotherapy for malignant ascites

目的:探讨多西他赛联合顺铂腹腔热灌注治疗(hyperthermic intraperitoneal chemotherapy,HIPEC)晚期肿瘤恶性腹水的临床疗效。方法:收集并分析2012年1月至2013年1月确诊为腹膜转移癌伴腹水患者40例。依据治疗方式不同,将其分为两组,观察组患者20例,进行多西他赛联合顺铂腹腔热灌注治疗。对照组患者20例,进行单纯腹腔化疗,两组患者治疗周期为1次/周,4周为1疗程,直至疾病进展,评价两组患者的治疗效果。结果:观察组患者的治疗总有效率为75.0%,对照组患者的治疗总有效率为35.0%,观察组患者治疗总有效率明显高于对照组(P<0.05);与对照组相比,观察组患者的肿瘤标志物癌胚抗原(carcino-embryonic antigen,CEA)、CA125降低(P<0.05);观察组患者中位无进展生存期(median progression free survival,m PFS)和中位总生存期(median overall survival,m OS)长于对照组(P<0.05)。结论:多西他赛联合顺铂腹腔热灌注治疗恶性腹水具有一定临床疗效,且不良反应轻。

Objective：To observe the clinical effect of docetaxel combined with cisplatin hyperthermic intraperitoneal chemotherapy （HIPEC） for malignant ascites. Methods：40 patients with peritoneal metastatic carcinoma and ascites diagnosed between January 2012 and January 2013 were collected and analyzed. On the basis of different treatment, the patients were divided into two groups, the observation group and the control group, with 20 cases in each group. The former group was given docetaxel combined with HIPEC and the latter group was given intraperitoneal chemotherapy alone. The treatment cycle of the two groups was once per week, and 4 weeks were one treatment course. The therapeutic effect of the two groups was compared till disease progression. Results：The total effective rate in the observation group was 75 %, and thai of the control group was 35 %, the observation group better than the control group （ P 〈 0.05 ） ; Compared with the control group, abdominal tumor markers CEA, and CA125 in the observation group dropped, with difference statistically significant （ P 〈 0.05 ） ; The median progression -free survival （mPFS） and the median overall survival （mOS） in the observation group were significantly longer than those in the control group （ P 〈 0.05 ）. Conclusion： Docetaxel combined with HIPEC in treatment of malignant ascites has certain clinical curative effect, with light adverse reaction.